NeuroPace Inc
NPCENasdaq
$16.08
↓ -2.4%Jul 17 close · end-of-day
Price
1Y↑ +76.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$542.2M
Enterprise Value
$547.2M
P/E
—
P/S
5.4
P/B
37.5
EV/EBITDA
—
PEG
—
FCF Yield
-1.8%
Dividend Yield
0.0%
Revenue (TTM)
$99.5M
Net Income (TTM)
-$21.6M
Free Cash Flow (TTM)
-$9.8M
Gross Margin
78.3%
Operating Margin
-16.8%
Net Margin
-21.7%
ROE
-149.2%
ROIC
-67.9%
Debt / Equity
4.1
Net Cash
-$5.0M
Return 1Y
+77.1%
Company profile
NeuroPace, Inc. develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company was incorporated in 1997 and is headquartered in Mountain View, California.
- CEO
- Michael Favet
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 170
- Headquarters
- California
- Website
- www.neuropace.com
Management & directors
- Morrell MarthaCHIEF MEDICAL OFFICER
- Becker JoelCHIEF EXECUTIVE OFFICER
- Williams Patrick F.Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
NPCE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$22.1M↓ -2.0%
Diluted EPS-$0.20↓ -4.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.1M | $45.2M | $45.5M | $65.4M | $79.9M | $100.0M |
| Gross profit | $30.3M | $33.4M | $32.5M | $48.1M | $59.1M | $77.2M |
| Operating income | -$13.1M | -$23.7M | -$40.8M | -$27.2M | -$21.7M | -$16.3M |
| Net income | -$24.3M | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M |
| Diluted EPS | -$117.85 | -$2.17 | -$1.91 | -$1.27 | -$0.93 | -$0.66 |
| Operating cash flow | -$21.6M | -$24.6M | -$36.9M | -$19.7M | -$17.9M | -$11.0M |
| Free cash flow | -$21.7M | -$25.0M | -$37.5M | -$19.9M | -$18.3M | -$11.3M |
| Gross margin | 73.6% | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% |
| Operating margin | -31.7% | -52.5% | -89.6% | -41.5% | -27.1% | -16.3% |
| Net margin | -59.0% | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.3M | $21.1M | $21.5M | $22.5M | $23.5M | $27.4M | $26.6M | $22.1M |
| Gross profit | $14.1M | $15.4M | $16.2M | $17.3M | $18.1M | $21.2M | $20.6M | $18.0M |
| Operating income | -$6.2M | -$4.2M | -$3.7M | -$5.1M | -$6.8M | -$2.6M | -$1.8M | -$5.6M |
| Net income | -$7.5M | -$5.5M | -$5.3M | -$6.6M | -$8.7M | -$3.5M | -$2.7M | -$6.7M |
| Diluted EPS | -$0.26 | -$0.19 | -$0.16 | -$0.21 | -$0.26 | -$0.11 | -$0.08 | -$0.20 |
| Operating cash flow | -$3.9M | -$1.7M | -$4.8M | -$7.5M | -$2.1M | -$1.9M | $506,000.00 | -$5.9M |
| Free cash flow | -$4.0M | -$1.8M | -$4.8M | -$7.5M | -$2.3M | -$2.0M | $409,000.00 | -$6.0M |
| Gross margin | 73.4% | 73.2% | 75.4% | 77.0% | 77.1% | 77.4% | 77.4% | 81.8% |
| Operating margin | -32.4% | -20.1% | -17.0% | -22.9% | -29.0% | -9.5% | -6.6% | -25.2% |
| Net margin | -39.0% | -25.9% | -24.5% | -29.3% | -36.8% | -12.8% | -10.3% | -30.3% |
Company news
Jul 15, 2026
Jun 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-24 | Morrell Martha· CHIEF MEDICAL OFFICER | Tax withholding | 335 | $16.22 | $5,433.70 | filing |
| 2026-06-19 | Fischer Frank M | Award | 1,467 | $15.63 | $22,929.21 | filing |
| 2026-06-19 | Kumar Rakhi | Award | 989 | $15.63 | $15,458.07 | filing |
| 2026-06-19 | Geiger Uri | Award | 789 | $15.63 | $12,332.07 | filing |
| 2026-06-05 | Ryan Renee | Award | 2,890 | $0.00 | $0.00 | filing |
| 2026-06-05 | Andrade Lisa | Award | 2,890 | $0.00 | $0.00 | filing |
| 2026-06-05 | Geiger Uri | Award | 2,890 | $0.00 | $0.00 | filing |
| 2026-06-05 | Huennekens R Scott | Award | 2,890 | $0.00 | $0.00 | filing |
| 2026-06-05 | Fischer Frank M | Award | 2,890 | $0.00 | $0.00 | filing |
| 2026-06-05 | Kumar Rakhi | Award | 2,890 | $0.00 | $0.00 | filing |
| 2026-06-03 | Becker Joel· CHIEF EXECUTIVE OFFICER | Tax withholding | 1,255 | $15.88 | $19,929.40 | filing |
| 2026-05-27 | Becker Joel· CHIEF EXECUTIVE OFFICER | Tax withholding | 1,126 | $17.06 | $19,209.56 | filing |
| 2026-05-27 | Morrell Martha· CHIEF MEDICAL OFFICER | Tax withholding | 358 | $17.06 | $6,107.48 | filing |
| 2026-05-15 | Williams Patrick F.· Chief Financial Officer | Award | 16,820 | $0.00 | $0.00 | filing |
| 2026-05-15 | Morrell Martha· CHIEF MEDICAL OFFICER | Award | 5,460 | $0.00 | $0.00 | filing |
| 2026-05-15 | Becker Joel· CHIEF EXECUTIVE OFFICER | Award | 45,880 | $0.00 | $0.00 | filing |
| 2026-03-24 | Morrell Martha· CHIEF MEDICAL OFFICER | Tax withholding | 1,341 | $13.27 | $17,795.07 | filing |
| 2026-03-20 | Fischer Frank M | Award | 1,826 | $13.00 | $23,738.00 | filing |
| 2026-03-20 | Kumar Rakhi | Award | 1,153 | $13.00 | $14,989.00 | filing |
| 2026-03-20 | Geiger Uri | Award | 913 | $13.00 | $11,869.00 | filing |
| 2026-03-20 | LACOB JOSEPH | Award | 865 | $13.00 | $11,245.00 | filing |
| 2026-03-03 | Becker Joel· CHIEF EXECUTIVE OFFICER | Tax withholding | 5,023 | $13.83 | $69,468.09 | filing |
| 2026-03-03 | Morrell Martha· CHIEF MEDICAL OFFICER | Tax withholding | 1,340 | $13.83 | $18,532.20 | filing |
| 2026-03-03 | Morrell Martha· CHIEF MEDICAL OFFICER | Tax withholding | 1,340 | $13.83 | $18,532.20 | filing |
| 2026-02-27 | Becker Joel· CHIEF EXECUTIVE OFFICER | Tax withholding | 1,126 | $14.58 | $16,417.08 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.